SpA, Spondylitis, Ankylosing
Conditions
Brief summary
Subjects will be given 3 infusions of infliximab according to the label at week 0, 2, and 6. Subjects will be followed for a maximum of 18 weeks or until relapse. This study will assess the ability of the Power Doppler Ultrasonography (PDUS) to be a reliable marker of enthesitis response and relapse in subjects treated with infliximab.
Interventions
PROCEDUREPDUS
PDUS scored for each enthesitis every 2 weeks for 24 weeks.
DRUGInfliximab
* 5 mg/kg * IV * Frequency : weeks 0,2,6
Sponsors
Centocor, Inc.
Merck Sharp & Dohme LLC
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Demonstrate willingness to participate in study, adhere to dose and visit schedules, and comply with procedures by signing a written informed consent. * Negative serum pregnancy test at Week 0. * Men and women over 18 years of either sex and any race. * Free of any clinically relevant disease other than SpA that would in the principal investigator's and/or sponsor's opinion, interfere with the conduct of study or its evaluations. * Eligible for anti-tumor necrosis factor (TNF) treatment according to applicable local guidelines. * Fulfill the following criteria: European Spondyloarthropathy Study group (ESSG) Classification Criteria, and/or Amor Criteria, and/or New York modified criteria. * Disease duration of SpA \>6 months. * Incomplete response to non-steriodal anti-inflammatory drug (NSAID). * Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) \>4 including item 2 (axial pain) \>=3 on a scale from 0 to 10. * At least 1 enthesitis assessed by PDUS. * C-reactive protein (CRP) twice upper normal laboratory value or inflammatory signal on magnetic resonance imaging (MRI) of spine or sacroiliac joint within the last 3 months. * Practicing adequate contraception during the study and for 6 months after last infusion. * Week 0 laboratory tests must meet protocol criteria.
Exclusion criteria
* Is a female who is pregnant, or intends to become pregnant during the study (or within 6 months after receiving the last infusion); * Is a female who is nursing, or intends to be nursing during the study or within 6 month after having received the last infusion; * Has childbearing potential without contraception throughout the study and for 6 months after receiving the last infusion. * Has not observed the designated washout periods for any of the prohibited medications outlined in the protocol; * Has any clinically significant deviation from the appropriate reference range in the physical examination, Chest X-ray, that, in the investigator's judgment, may interfere with the study evaluation or affect subject safety; * Is in a situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study. * Is on the staff, affiliated with, or a family member of the staff personnel directly involved with this study; * Is allergic to or has sensitivity to the study drug or its excipients; * Has intolerance to or contraindication for infliximab. * Has an history of allergy to murine products. * Is uncooperative or has not signed the consent form. * Cannot understand the protocol. * Has participated in a study within 3 months prior to inclusion. * Had treatment with unstable doses of analgesic drugs (paracetamol, phenylbutazone, morphine) steroid, NSAID, or immunosuppressive agent, including methotrexate, within 4 weeks prior to inclusion. * Had Intra articular steroid within 4 weeks prior to inclusion. * Had Previous treatment with infliximab * Had previous treatment with etanercept, adalimumab or any other TNF agent within 2 last months. * Had an history of, ongoing or recurrent medical condition as follows : * Infectious disease, including but not limited to chronic renal infection, chronic chest infection (e.g. bronchectasis), sinusitis, recurrent urinary tract infection (recurrent pyelonephritis or chronic nonremeting cystitis) open, draining or infected skin wound, or ulcer. Serious infection(s) (such as hepatitis, pneumonia or pyelonephritis) within 3 months prior to inclusion. * Malignancy within the previous 5 years with the exception of basal cell carcinoma of the skin that has been treated with no evidence of recurrence. * Active tuberculosis or previous history of non treated or insufficiently treated tuberculosis. * Patients with a positive intradermal tuberculosis test according to the local recommendation * For the patients who could have been in contact with a person having tuberculosis, the inclusion will be possible under specific conditions depending of local recommendations issued in France, Denmark, Hungary, Italy, Spain. * Herpes zoster (shingles) infection within 2 months prior to the first infusion * Opportunistic infections, e.g. cytomegalovirus, Pneumocystis carinii pneumonia, aspergillosis, histoplasmosis or atypical mycobacterium infection. * Has any of the following clinical conditions: * Severe, progressive or uncontrolled renal, hepatic, hematologic, gastrointestinal, endocrine, pulmonary, cardiac, neurologic, psychiatic or cerebral diseases * Known to be infected with human immunodeficiency virus (HIV), hepatitis B or hepatitis C * Known lymphoproliferative disease, including lymphoma, or signs suggestive of lymphoproliferative disease, such as lymphadenoma of unusual size and localization or splenomegaly. * Have received live (attenuated) vaccination during the last 30 days * Have been treated with a monoclonal antibody or a fusion protein except etanercept, adalimumab or any other anti TNF agent * Leukopenia \< 3,500/mm\^3, Hemoglobin \< 9g/dl, thrombopenia \< 100,000/mm\^3. * Congestive heart failure (CHF) including medically controlled, asymptomatic CHF or unstable hemodynamic cardiac conditions. * Scheduled surgical intervention at any time during the study. * Multiple sclerosis or symptomatic demyelination of central nervous system. * Subjects who have an history of drug abuse or alcoholism
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Number of Enthesitis Between Week 4 and Week 12 Evaluated Using Power Doppler Ultrasonography (PDUS) and Proprietary Software. | 8 weeks | Two measures were to be used for each enthesis evaluation. 1.) Vascularization: yes/no. 2.) Area of hyper-vascularization: mm\^2 (continuous) using proprietary software. This study was terminated early due to slow recruitment. As a result, efficacy analyses were not performed. |
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Infliximab 5 mg/kg Infliximab infusions: 5 mg/kg at weeks 0, 2, and 6. | 7 |
| Total | 7 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Protocol Violation | 4 |
| Overall Study | Relapse | 2 |
Baseline characteristics
| Characteristic | Infliximab 5 mg/kg |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 7 Participants |
| Sex: Female, Male Female | 1 Participants |
| Sex: Female, Male Male | 6 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | — / — |
| other Total, other adverse events | 2 / 7 |
| serious Total, serious adverse events | 0 / 7 |
Outcome results
Primary
The Number of Enthesitis Between Week 4 and Week 12 Evaluated Using Power Doppler Ultrasonography (PDUS) and Proprietary Software.
Two measures were to be used for each enthesis evaluation. 1.) Vascularization: yes/no. 2.) Area of hyper-vascularization: mm\^2 (continuous) using proprietary software. This study was terminated early due to slow recruitment. As a result, efficacy analyses were not performed.
Time frame: 8 weeks
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Infliximab 5 mg/kg | The Number of Enthesitis Between Week 4 and Week 12 Evaluated Using Power Doppler Ultrasonography (PDUS) and Proprietary Software. | 0 Number of Enthesitis |